Table of Content PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 06: Market segmentation by product • Market overview • Instruments • Consumables (blood culture bottles, reagents and assay kits) PART 07: Market segmentation by application • Bacteremia • Fungemia • Mycobacteria PART 08: Market segmentation by technology • Market overview • Conventional blood stream infection test • Point of care testing (POCT) • Nucleic acid testing PART 09: Market segmentation by end-user • Hospitals • Diagnostic clinical laboratories PART 10: Geographical segmentation • Blood stream infection market in Americas • Blood stream infection tests market in EMEA • Blood stream infection tests market in APAC PART 11: Market drivers • Rising incidence of hospital acquired infection increases patient volume • Patient-centered healthcare by digital technology • Growing awareness of blood donation increasing the demand for BSI testing market PART 12: Impact of drivers PART 13: Market challenges • High cost of instruments restricts market growth • Lack of favorable reimbursement reduces adoption rate among patients • Stringent regulatory policies restrict entry of new technologies PART 14: Impact of drivers and challenges PART 15: Market trends • Focus on early diagnosis • Technologically advanced tests save time and cost • Increasing demand for infection control committee in hospitals PART 16: Vendor landscape • Competitive scenario • BD • bioMérieux • Cepheid • Roche Diagnostics • Thermo Fisher Scientific • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Mortality rate of community acquired blood stream infections per year in different regions Exhibit 03: Global blood stream infection testing market 2015-2020 ($ millions) Exhibit 04: Global blood stream infection testing market overview Exhibit 05: Five forces analysis Exhibit 06: Global blood stream infection testing market by products 2015-2020 (%) Exhibit 07: Market strategy analysis of instruments segment Exhibit 08: Global blood stream infection testing instruments market 2015-2020 ($ millions) Exhibit 09: Market strategy analysis of consumable segment Exhibit 10: Global blood stream infection testing consumables market 2015-2020 ($ millions) Exhibit 11: Top ten bacterimia blood stream infections in 2015 Exhibit 12: Global blood stream infections testing market by products Exhibit 13: Global blood stream infection testing market share by technology 2015-2020 (%) Exhibit 14: Global conventional blood stream infection testing market 2015-2020 ($ millions) Exhibit 15: The laboratory and POC testing process Exhibit 16: Global blood stream infection testing market by end-user 2015-2020 (%) Exhibit 17: Blood stream infection testing market revenue in the Americas 2015-2020 ($ millions) Exhibit 18: Blood stream infection testing market in Americas Exhibit 19: Blood stream infection testing market revenue in EMEA 2015-2020 ($ millions) Exhibit 20: Blood stream infection testing market in EMEA Exhibit 21: Blood stream infection testing market revenue in APAC 2015-2020 ($ millions) Exhibit 22: Blood stream infection testing market in APAC Exhibit 23: Impact of driver Exhibit 24: Price of different sequencers of different companies Exhibit 25: Government regulatory stages of blood stream infection devices and consumables Exhibit 26: Impact of drivers and challenges Exhibit 27: Reasons for hospital acquired blood stream infection Exhibit 28: Competitive structure of vendors in blood stream infection testing market Exhibit 29: Strength assessment Exhibit 30: BD: Strategy assessment Exhibit 31: BD opportunity assessment Exhibit 32: bioMérieux strength assessment Exhibit 33: bioMérieux strategy assessment Exhibit 34: bioMérieux: Opportunity assessment Exhibit 35: Cepheid: Strength assessment Exhibit 36: Cepheid: Strategy assessment Exhibit 37: Cepheid opportunity assessment Exhibit 38: Roche Diagnostics: Strength assessment Exhibit 39: Roche Diagnostics: Strategy assessment Exhibit 40: Roche Diagnostics: Opportunity assessment Exhibit 41: Thermo Fisher Scientific: Strength assessment Exhibit 42: Thermo Fisher Scientific: Strategy assessment Exhibit 43: Thermo Fisher Scientific: Opportunity assessment

BD, bioMérieux, Cepheid, Roche Diagnostics, Thermo Fisher, IRIDICA, Alere, Beckman Coulter, Bruker, Nanosphere, Siemens, Dade Behring, AdvanDX, Eurogentec, AB Sciex.